The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.
 
Damien Vasseur
No Relationships to Disclose
 
Cécile Jovelet
No Relationships to Disclose
 
Nathalie Cozic
No Relationships to Disclose
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Hengrui Therapeutics; Lilly/ImClone; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Seagen; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
 
Jaafar Bennouna
Honoraria - Amgen; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; roche; SERVIER
Consulting or Advisory Role - AMGEN; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
 
Radj Gervais
No Relationships to Disclose
 
Lionel Moreau
No Relationships to Disclose
 
Henri Berard
Consulting or Advisory Role - BMS
Travel, Accommodations, Expenses - BMS; BMS; MSD; Novartis; Roche; ROCHE
 
Olivier Molinier
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Takeda
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Denis Moro-Sibilot
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly/ImClone; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim France (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Expert Testimony - MSD Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly/ImClone; MSD Oncology; Pfizer; Roche/Genentech
 
Pierre Jean Souquet
No Relationships to Disclose
 
Elodie Amour
No Relationships to Disclose
 
Franck Morin
No Relationships to Disclose
 
Gerard Zalcman
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Inventiva Pharma; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Inventiva Pharma (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst); ROCHE (Inst); ROCHE (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Pfizer; Roche
 
Jean-Charles Soria
Employment - AstraZeneca
Leadership - Hookipa Pharma
Stock and Other Ownership Interests - AstraZeneca; Daiichi Sankyo; Gritstone Bio
Consulting or Advisory Role - Relay Therapeutics
 
Virginie Westeel
Leadership - Bristol-Myers Squibb; Roche; Takeda
Honoraria - MSD Oncology
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Roche
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Pfizer; Roche
 
Ludovic Lacroix
No Relationships to Disclose
 
Benjamin Besse
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cergentis (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Janssen Oncology (Inst); Lilly (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst)